Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q4 FY23 results · Jan–Mar 2023
Lincoln Pharmaceuticals reported revenue from operations of ₹112.46 crore (up 9.6% from Q4 FY22) and net profit of ₹12.56 crore (up 13.9% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a consolidated basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.46 | 102.59 | +9.6% | 133.77 | −15.9% |
| Other income | 3.90 | 1.89 | +106.2% | 6.36 | −38.7% |
| Total income | 116.36 | 104.48 | +11.4% | 140.12 | −17.0% |
| Profit before tax | 16.98 | 16.77 | +1.2% | 30.51 | −44.4% |
| Net profit for the period | 12.56 | 11.02 | +13.9% | 21.61 | −41.9% |
| EPS, basic (₹) | 6.27 | 5.50 | +14.0% | 10.79 | −41.9% |
| Net margin (%) | 11.2 | 10.7 | 16.2 |
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 112.46 | 102.54 | +9.7% | 133.77 | −15.9% |
| Other income | 3.95 | 1.89 | +108.7% | 6.36 | −37.9% |
| Total income | 116.41 | 104.43 | +11.5% | 140.12 | −16.9% |
| Profit before tax | 16.98 | 16.76 | +1.3% | 30.52 | −44.4% |
| Net profit for the period | 12.56 | 11.02 | +13.9% | 21.61 | −41.9% |
| EPS, basic (₹) | 6.27 | 5.50 | +14.0% | 10.79 | −41.9% |
| Net margin (%) | 11.2 | 10.8 | 16.2 |
Consolidated
- Filed with BSE
- 25 May 2023, 17:16 IST
- Board meeting
- 25 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 25 May 2023, 17:16 IST
- Board meeting
- 25 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE